OCI-LY3 Cells
CAD$593.40*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | OCI-LY3 is a human diffuse large B-cell lymphoma (DLBCL) cell line derived from the malignant lymph node of a patient with activated B-cell-like (ABC) subtype DLBCL. This subtype is associated with a poorer prognosis compared to other forms of DLBCL and is characterized by constitutive activation of the NF-κB signaling pathway. As a representative model of ABC-DLBCL, OCI-LY3 is widely utilized in lymphoma research, particularly for studying tumor biology, identifying molecular vulnerabilities, and testing novel therapeutic strategies. OCI-LY3 cells grow in suspension and exhibit features typical of malignant B cells, including the expression of surface markers associated with mature B-cell lineage. The cell line harbors key genetic alterations commonly observed in ABC-DLBCL, such as mutations affecting the B-cell receptor (BCR) signaling pathway, Toll-like receptor signaling, and components of the NF-κB pathway, including CARD11 and MYD88. These features make OCI-LY3 particularly suitable for investigating the molecular mechanisms driving NF-κB activation, a hallmark of ABC-DLBCL, and its role in promoting cell survival and resistance to apoptosis. OCI-LY3 is an essential model for preclinical studies aimed at evaluating the efficacy of targeted therapies, including inhibitors of NF-κB signaling, BCR signaling, and anti-apoptotic proteins such as BCL-2. Researchers also use this cell line to study mechanisms of drug resistance and to test combination therapies designed to overcome resistance in aggressive lymphoma subtypes. Its relevance to the ABC subtype of DLBCL makes OCI-LY3 an invaluable resource for advancing the understanding of this high-risk lymphoma and for developing novel, more effective treatments. |
|---|---|
| Organism | Human |
| Tissue | Bone Marrow |
| Disease | B-cell lymphoma |
| Synonyms | OCI-LY3, OCI-ly3, OCI-LY-3, Oci-Ly-3, OCI-Ly 3, OCILY-3, OCI-Ly03, OCI Ly3, OCILY3, Ly3, LY3 |
Characteristics
| Age | 52 years |
|---|---|
| Gender | Male |
| Ethnicity | Caucasian |
| Morphology | Epithelial-like |
| Growth properties | Suspension |
Regulatory Data
| Citation | OCI-LY3 (Cytion catalog number 305480) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_8800 |
Biomolecular Data
| Antigen expression | CD3 -, CD10 -, CD13 -, CD19 (+), CD20 +, CD34 -, CD37 +, cyCD79a +, CD80 +, CD138 -, HLA-DR +, sm/cyIgG +, sm/cyIgM -, sm/cykappa -, sm/cylambda +; in the referenced paper this cell line is described as cykappa +; |
|---|---|
| Viruses | HBV -, HCV -, HIV-1 -, HIV-2 -, MLV - |
| Mutational profile | Gene Fusion: IGH + HGNC, 11242, SPIB, Name(s)=IGH-SPIB; Mutation: CARD11, Simple, p.Leu251Pro (c.752T>C) (L244P), Homozygous; Mutation: MYD88, Simple, p.Leu252Pro (c.755T>C) (L265P), Homozygous |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 20% FBS |
| Doubling time | 24 hours |
| Subculturing | Seed out at ca. 0.2-0.3 x 106 cells/ml, at best in a 12- or 24-well plate; after thawing cell viability may be as low as 50%, but cells should recover quickly within a week; |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|